Catalyst
Slingshot members are tracking this event:
Celgene (CELG) Phase III data readout of AUGMENT trial testing Revlimid in treating relapsed and/or refractory Follicular lymphoma expected by end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CELG | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 23, 2018
Occurred Source:
http://ir.celgene.com/releasedetail.cfm?ReleaseID=1072723
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Revlimid, Augment, Indolent Non-hodgkin Lymphoma, Phase 3 Study
